explore -WSS

explore

author：hotspot 2025-10-02 00:43:01 - browse：681

Two people stare at a keyhole in a human head in between them, as the short-haired person on the left holds a key — first opinion coverage from STAT — Adobe

In many ways, psychiatry is still flying blind. People experiencing mental health conditions are prescribed various drugs until one (or a combination) finally works — a painful process that can take years. As a psychiatrist and neuroscientist, I became increasingly impatient and frustrated with this ineffective way of treating patients. This guided the core question behind my research: Can biology explain how people with the same psychiatric disorder respond differently to the same treatment?

Since I first began exploring this question more than a decade ago, mental illness has become a global epidemic. Despite significant efforts, progress in psychiatric drug development has remained disappointingly slow. There have been a few notable approvals in recent years, and a renewal of interest by Big Pharma, following a retreat from psychiatric research in the mid to late 2000s. But the landscape remains predominantly marked by failures and a dry drug development pipeline. Approved drugs follow the same pattern of prescribing via guesswork, with most patients not responding to a given drug. This cycle of trial-and-error drug development producing trial-and-error treatment arises from a simple source: We have not systematized a process for learning from our failures and successes.

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

For example, take depression: While the rise of selective serotonin reuptake inhibitors (SSRIs) in the 1980s and 1990s seemed to provide a solution, seminal studies in the 2000s exposed fundamental limitations of our treatment options. Antidepressants are widely prescribed, but their efficacy relative to placebo is modest.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： CDC advisory panel says seniors 'may' get RSV vaccine

knowledge

WSS

AstraZeneca bets AAV gene therapy will still deliver the goods

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Radiation, mainstay of cancer treatment, begins a fade

Psilocybin's anti

Pediatric cancer treatments threatened by a new FDA policy

Medicare explains how it will choose drugs for negotiation

entertainment

explore

Related: A ‘renaissance in neuroscience’ could deliver a fresh crop of psychiatric medicines

knowledge

Malaria cases in Florida and Texas: Here’s what you need to know

Disappointing trial forces Pfizer to pivot on obesity medicine plans

23andMe had bad news about my health. I wish a person had delivered it

Cigna, Humana reportedly in talks to merge

Tori Bowie and the unacceptable rates of Black maternal death

Feds fine Medicare Advantage plans for overcharging members

George Santos makes 1st court appearance after pleading not guilty to 13 counts

FDA panel gives mixed vote on blood pressure devices

BioMarin wins approval for gene therapy to treat hemophilia A

Will the market for weight loss drugs really reach $100 billion?

entertainment

FDA panel gives mixed vote on blood pressure devices

Apellis safety probe of eye disease drug centers on injection needle

CDC director unscathed in first congressional testimony

What do new weight loss drugs mean for bariatric surgery?

Fetal surgery at risk from Dobbs and new abortion restrictions

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

knowledge

explore

focus

hotspot